WO2013188016A3 - Thérapie utilisant des surfactants pour exposition à un rayonnement ionisant - Google Patents

Thérapie utilisant des surfactants pour exposition à un rayonnement ionisant Download PDF

Info

Publication number
WO2013188016A3
WO2013188016A3 PCT/US2013/039592 US2013039592W WO2013188016A3 WO 2013188016 A3 WO2013188016 A3 WO 2013188016A3 US 2013039592 W US2013039592 W US 2013039592W WO 2013188016 A3 WO2013188016 A3 WO 2013188016A3
Authority
WO
WIPO (PCT)
Prior art keywords
ionizing radiation
exposure
surfactant
pulmonary
surfactant therapy
Prior art date
Application number
PCT/US2013/039592
Other languages
English (en)
Other versions
WO2013188016A2 (fr
Inventor
Robert Segal
Melpo Christofidou-Solomidou
Original Assignee
Discovery Laboratories, Inc.
The Trustees Of The University Of Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Discovery Laboratories, Inc., The Trustees Of The University Of Pennsylvania filed Critical Discovery Laboratories, Inc.
Publication of WO2013188016A2 publication Critical patent/WO2013188016A2/fr
Publication of WO2013188016A3 publication Critical patent/WO2013188016A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/395—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0082—Lung surfactant, artificial mucus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des thérapies pour le traitement ou la prévention d'états résultant d'une exposition directe ou indirecte du tissu pulmonaire à un rayonnement ionisant. En particulier, des régimes de traitement ou de prévention d'états résultant d'une exposition directe ou indirecte du tissu pulmonaire à un rayonnement ionisant impliquent l'administration de surfactants pulmonaires. Dans certains modes de réalisation, le surfactant pulmonaire est un surfactant KL4.
PCT/US2013/039592 2012-05-04 2013-05-04 Thérapie utilisant des surfactants pour exposition à un rayonnement ionisant WO2013188016A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261642856P 2012-05-04 2012-05-04
US61/642,856 2012-05-04
US201361794036P 2013-03-15 2013-03-15
US61/794,036 2013-03-15

Publications (2)

Publication Number Publication Date
WO2013188016A2 WO2013188016A2 (fr) 2013-12-19
WO2013188016A3 true WO2013188016A3 (fr) 2014-04-10

Family

ID=48875145

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/039592 WO2013188016A2 (fr) 2012-05-04 2013-05-04 Thérapie utilisant des surfactants pour exposition à un rayonnement ionisant

Country Status (1)

Country Link
WO (1) WO2013188016A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109689043A (zh) * 2016-06-07 2019-04-26 宾夕法尼亚大学 用于保护器官免受与移植相关的缺血/再灌注损伤的组合物和方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060078506A1 (en) * 2004-05-20 2006-04-13 Ralph Niven Methods, systems and devices for noninvasive pulmonary delivery
WO2006055532A2 (fr) * 2004-11-15 2006-05-26 Discovery Laboratories, Inc. Procedes de production de formulations de tensioactifs pulmonaires par lyophilisation et formulations et utilisations correspondantes
WO2007005672A2 (fr) * 2005-06-30 2007-01-11 The Scripps Research Institute Traitement et prevention de maladies et de situations respiratoires
US20100317565A1 (en) * 2007-06-04 2010-12-16 Rentschler Beteiligungs Gmbh Novel Peptides and Their Use for the Treatment of Edema
EP1558273B1 (fr) * 2002-04-25 2011-08-17 The Scripps Research Institute Traitement et prevention d'affections pulmonaires
US8337815B2 (en) * 2004-12-23 2012-12-25 Discovery Laboratories, Inc. Pulmonary surfactant formulations

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US574325A (en) 1896-12-29 Joseph s
US502495A (en) 1893-08-01 klijsel
US4659805A (en) 1984-12-11 1987-04-21 California Biotechnology, Inc. Recombinant alveolar surfactant protein
US5840527A (en) 1984-12-11 1998-11-24 Byk Gulden Lomberg Chemische Fabrik Gmbh Recombinant alveolar surfactant protein
US4918161A (en) 1985-09-26 1990-04-17 Genetics Institute, Inc. Low molecular weight pulmonary surfactant proteins
WO1989004326A1 (fr) 1987-11-04 1989-05-18 California Biotechnology Inc. Proteines a effet tensio-actif alveolaire
US6013619A (en) 1988-01-06 2000-01-11 The Scripps Research Institute Pulmonary surfactants and therapeutic uses, including pulmonary lavage
US5260273A (en) 1988-01-06 1993-11-09 The Scripps Research Institute Pulmonary surfactant protein and related polypeptide
US5164369A (en) 1988-01-06 1992-11-17 The Scripps Research Institute Pulmonary surfactant protein and related polypeptide
US6613734B2 (en) 1988-01-06 2003-09-02 The Scripps Research Institute Peptides-containing liposomal surfactants
US4861756A (en) 1988-03-08 1989-08-29 Merrell Dow Pharmaceuticals Inc. Synthetic pulmonary surfactant
SE8803713D0 (sv) 1988-10-18 1988-10-18 Kabigen Ab Biologically active lipoprotein and its use
US5006343A (en) 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances
US5238920A (en) 1989-08-22 1993-08-24 Abbott Laboratories Pulmonary surfactant protein fragments
EP0458167B1 (fr) 1990-05-21 1997-04-23 Abbott Laboratories Conjugés acide gras-tensioactif pulmonaire
US5272252A (en) 1991-11-04 1993-12-21 Merrell Dow Pharmaceuticals Inc. Synthetic lung surfactant having antioxidant properties
ES2192190T3 (es) 1992-04-10 2003-10-01 Abbott Lab Fragmentos proteicos tensioactivos pulmonares.
US5302481A (en) 1993-06-07 1994-04-12 Xerox Corporation Toner compositions with negative charge enhancing complexes
RO118298B1 (ro) 1993-12-08 2003-04-30 Tokyo Tanabe Co Peptida sintetica, procedeu pentru prepararea acesteia, surfactantul pulmonar si agentul terapeutic continand aceasta peptida
DE4418936A1 (de) 1994-05-31 1996-02-08 Byk Gulden Lomberg Chem Fab Polypeptid
DE4434629C1 (de) 1994-09-28 1996-06-27 Byk Gulden Lomberg Chem Fab Zusammensetzungen zur Behandlung von IRDS und ARDS
WO1997035882A1 (fr) 1996-03-27 1997-10-02 Ortho Pharmaceutical Corporation Compositions lyophilisees de peptides tensioactifs pulmonaires
US6120795A (en) 1996-03-27 2000-09-19 Ortho Pharmaceutical Corp. Manufacture of liposomes and lipid-protein complexes by ethanolic injection and thin film evaporation
US6013764A (en) 1996-07-17 2000-01-11 Ortho Pharmaceutical Corp. Liquid phase peptide synthesis of KL-4 pulmonary surfactant
US6573253B2 (en) 1997-02-12 2003-06-03 Medimmune Oncology Inc. Methods for the administration of amifostine and related compounds
US6660833B1 (en) 2000-02-29 2003-12-09 Harbor-Ucla Research And Education Institute Respiratory distress syndrome therapy with peptide analogs of human SP-B
CA2497845C (fr) 2002-09-06 2012-08-14 Chrysalis Technologies Incorporated Formulations liquides d'aerosol, generateurs aerosols et procedes de generation d'aerosols
WO2009102818A1 (fr) 2008-02-11 2009-08-20 Cleveland Biolabs, Inc. Procédé de réduction des effets de la chimiothérapie à l’aide de polypeptides associés à la flagelline
CA2718902C (fr) 2008-03-17 2014-05-06 Discovery Laboratories, Inc. Adaptateur de circuit de ventilation et systeme de distribution d'aerosol proximal
JP2012503014A (ja) 2008-09-19 2012-02-02 マキシジェン， インコーポレイテッド マルチ−ｐｅｇ化顆粒球コロニー刺激因子（ｇ−ｃｓｆ）変異体の投与による放射線誘発好中球減少症の処置のための方法

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1558273B1 (fr) * 2002-04-25 2011-08-17 The Scripps Research Institute Traitement et prevention d'affections pulmonaires
US20060078506A1 (en) * 2004-05-20 2006-04-13 Ralph Niven Methods, systems and devices for noninvasive pulmonary delivery
WO2006055532A2 (fr) * 2004-11-15 2006-05-26 Discovery Laboratories, Inc. Procedes de production de formulations de tensioactifs pulmonaires par lyophilisation et formulations et utilisations correspondantes
US8337815B2 (en) * 2004-12-23 2012-12-25 Discovery Laboratories, Inc. Pulmonary surfactant formulations
EP1833503B1 (fr) * 2004-12-23 2013-07-31 Discovery Laboratories, Inc. Formulations de tensioactif pulmonaire
WO2007005672A2 (fr) * 2005-06-30 2007-01-11 The Scripps Research Institute Traitement et prevention de maladies et de situations respiratoires
US20100317565A1 (en) * 2007-06-04 2010-12-16 Rentschler Beteiligungs Gmbh Novel Peptides and Their Use for the Treatment of Edema

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Discovery Laboratories 10-K 2013", 15 March 2013 (2013-03-15), pages 1 - 133, XP055101943, Retrieved from the Internet <URL:http://www.wikinvest.com/stock/Discovery_Laboratories_(DSCO)/Filing/10-K/2013/F107474757> [retrieved on 20140213] *
ANONYMOUS: "Discovery Labs Initiates Research Projects with Leading Research Institutions and US Government Agencies to Assess KL4 Surfactant Utility in Acute Lung Injury", 27 September 2012 (2012-09-27), pages 1 - 3, XP055093034, Retrieved from the Internet <URL:http://www.discoverylabs.com/2012pr/092712-PR.pdf> [retrieved on 20131212] *
ANONYMOUS: "form10q.htm", 14 November 2012 (2012-11-14), pages 1 - 48, XP055093046, Retrieved from the Internet <URL:http://www.sec.gov/Archives/edgar/data/946486/000114036112047325/form10q.htm> [retrieved on 20131212] *
ANONYMOUS: "KL4 Surfactant to Mitigate Radiation-Induced Lung Injury | SBIR.gov", 2012, pages 1 - 2, XP055093121, Retrieved from the Internet <URL:http://www.sbir.gov/sbirsearch/detail/399806> [retrieved on 20131212] *
ANONYMOUS: "Project Information - 1R43AI102308-01 - Details", 19 June 2012 (2012-06-19), pages 1, XP055093058, Retrieved from the Internet <URL:http://projectreporter.nih.gov/project_info_details.cfm?aid=8393586&icde=0> [retrieved on 20131212] *
ANONYMOUS: "Project Information - 1R43AI102308-01", 19 June 2012 (2012-06-19), pages 1 - 2, XP055093053, Retrieved from the Internet <URL:http://projectreporter.nih.gov/project_info_description.cfm?aid=8393586&icde=0> [retrieved on 20131212] *
KRISHNAN RAGHAVENDRAN ET AL: "Surfactant Therapy for Acute Lung Injury and Acute Respiratory Distress Syndrome", CRITICAL CARE CLINICS, vol. 27, no. 3, 1 July 2011 (2011-07-01), pages 525 - 559, XP055093032, ISSN: 0749-0704, DOI: 10.1016/j.ccc.2011.04.005 *

Also Published As

Publication number Publication date
WO2013188016A2 (fr) 2013-12-19

Similar Documents

Publication Publication Date Title
PH12016501750A1 (en) Human plasma kallikrein inhibitors
IN2015DN01156A (fr)
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
MX356525B (es) Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia.
MX2017004471A (es) Compuestos de triazolopiridina y métodos para el tratamiento de fibrosis cística.
WO2014062720A3 (fr) Méthodes de traitement du cancer
ZA201308617B (en) Use of thiazolide compounds for the prevention and treatment of viral diseases, cancer and diseases caused by intracellular infections
IN2014DN09173A (fr)
WO2014028600A3 (fr) Composés 3-aminocycloalkyl utilisés en tant qu&#39;inhibiteurs de rorgammat et utilisations de ceux-ci
EA201590703A1 (ru) Ингибиторы mek при лечении вирусных заболеваний
MY169328A (en) Compositions for the treatment of dry eye
MX2015012882A (es) Compuestos y composiciones terapeuticos.
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
MX368903B (es) Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
MX2017005861A (es) Metodos para el control transcripcional objetivo en regiones del super mejorador.
EP3212658A4 (fr) Analogues de 2&#39;,2&#39;-dihalo-nucléosides utilisables en vue du traitement d&#39;infections par des virus de la famille des flaviviridae et du cancer
EP3065768A4 (fr) Thérapie pour le traitement ou la prévention d&#39;états associés au saignement ou à l&#39;hypocoagulation
EP3134423A4 (fr) Analogues de nucléosides disubstitués en 2&#39; pour le traitement des virus de la famille des flaviviridae et du cancer
WO2012158672A3 (fr) Composés utilisés dans le traitement de la mucosite
EA201491500A1 (ru) Способы лечения фиброза
EP4137147A3 (fr) Utilisations d&#39;abaloparatide pour réduire le risque de fracture
EP3206685A4 (fr) Prévention ou traitement de troubles du sommeil au moyen d&#39;une formulation de dexmédétomidine
WO2013185048A3 (fr) Inhibiteurs d&#39; atpase de type f1f0, à base de guanidine hétérocyclique et leurs utilisations thérapeutiques
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
HK1210417A1 (en) Compositions, methods and/or devices for prevention and/or treatment of dry eye disorders //

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13741890

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13741890

Country of ref document: EP

Kind code of ref document: A2